PMC:3724972 / 24814-25485 JSONTXT

{"project":"2_test","denotations":[{"id":"23673515-22105169-63233673","span":{"begin":481,"end":483},"obj":"22105169"}],"text":"The epidermal growth factor receptor (EGFR) family has recently been studied as a therapeutic target for CD. In cultured human and canine corticotroph tumors, gefitinib (an EGFR tyrosine kinase inhibitor) attenuated POMC expression, inhibited corticotroph tumor cell proliferation, and induced apoptosis. In murine studies, gefitinib decreased tumor size and corticosterone levels, and reversed signs of hypercortisolemia, including elevated glucose levels and excess omental fat [72]. These results indicate that inhibiting EGFR signaling may be a valuable strategy for treating CD. Further studies evaluating clinical efficacy and safety in patients with CD are needed."}